CD19 and cancer: Importantly, CD19+CD24hiIgDlo/−CD38lo and CD19+CD24hiIgDlo/−CD38hi Bregs from cancer patients showed a significantly stronger ability to inhibit T cell activation (as measured by IFNγ production) than those from healthy subjects (Fig. 5d, e, left).